Stock Idea - Punjab National Bank

Recommendation: Buy

CMP = Rs 550

Price target: Rs 675

Result highlights:

  • Punjab National Bank's (PNB) Q2FY2008 profit after tax (PAT) grew by 6.6% year on year (yoy) to Rs 538.5 crore. The PAT was higher than our expectations of Rs 510.5 crore and was mainly driven by the higher non-interest income.
  • The net interest income (NII) adjusted for amortisation expenses was stagnant at Rs 1,368.5 crore as higher deposit costs put a significant pressure on the net interest margin (NIM). The NIM declined by 11 basis points (bps) on a year-on-year (y-o-y) basis to 3.75%.
  • The non-interest income grew by 26.1% yoy to Rs 467.8 crore mainly driven by the higher treasury income that grew by 67.2% yoy to Rs 107 crore and a fee income that rose by 20.7% yoy to Rs 262 crore.
  • The operating expenses grew by 19.3% yoy to Rs 855 crore mainly on the back of a 25.6% y-o-y increase in the staff expenses to Rs 641.8 crore. The sharp increase in the staff expenses was on account of Rs 200-crore additional provisions made by the bank to meet its shortfall in pension liabilities.
  • The management has stated that the shortfall is likely to be around Rs 900 crore and is to be written over the next five years. Thus, the operating profit declined by 5% yoy, whereas the core operating profit was down by 10.3% yoy.
  • Despite the dismal performance on the core operating side, PNB continues to enjoy a high level of current account and savings account (CASA) at 44% and margins at around 3.8%. The bank owns a 25% stake in the Unit Trust of India (UTI) mutual fund. UTI is likely to come out with an initial public offer (IPO) in early CY2008. The stake in the UTI mutual fund contributes around Rs 32 to each share of PNB.
  • With its high return on equity (RoE) of around 17.8%, I feel the valuations are attractive at current levels. At the current market price of Rs 550, the stock is quoting at 7.8x its FY2009E earnings per share (EPS), 4x pre-provisioning profit (PPP) and 1.3x FY2009E book value (BV).
  • I maintain Buy recommendation on the stock with a 12-month price target of Rs 675.

Stock Idea - Subros

Recommendation: Buy

CMP = Rs 200 (as of Monday)

Price target: Rs 340

Result highlights:

  • Subros' Q2FY2008 results were slightly below our expectations due to a lower than expected topline. The net sales for the quarter declined by 5.3% to Rs 157.1 crore on the back of a 4.1% decline in the volumes due to a slower offtake by Tata Motors. 
  • The operating profit margin (OPM) improved by 130 basis points to 12.3% in Q2FY2008 from 11% in Q2FY2007 due to higher efficiencies, savings in logistics costs and localisation benefits.
  • Higher interest and depreciation charges led to a 17.4% decline in the net profits to Rs 6.4 crore. However, with majority of the capital expenditure (capex) incurred and with the low-cost debt recently raised by the company, we expect the interest costs to rationalise going forward.
  • The sharp improvement in the OPM has been a positive surprise and we believe that the company would be able to maintain the OPM at these levels going forward. The company has already bagged an order from Suzuki to supply compressors for its new export vehicle, which would boost Subros' FY2009 volumes.
  • At the current market price of Rs 200, the stock is available at very attractive valuations, discounting its FY2009E earnings by 4.9x and is available at enterprise value (EV)/earnings before interest, depreciation, tax, and amortisation (EBIDTA) of 2.6x.
  • Hence, I maintain extremely positive stance on Subros with a price target of Rs 340.

Stock Idea - State Bank of India & ICICI Bank

State Bank of India

Recommendation: Buy

CMP = Rs 2, 209

Price target: Rs 2,625

Key Points:

  • I have been mentioning that the banking sector would continue to remain an outperformer in the current market scenario and so it has, with the Sensex reporting a gain of 10% in the last one month and Bankex reporting a growth of 17% in the same period. 
  • The public sector behemoth State Bank of India (SBI) remains one of the top picks in the banking space and I have stated below five reasons why I feel SBI should be a Buy at the current levels:
  1. Upcoming rights issue—at a price far higher than envisaged earlier 
  2. Guidelines on holding companies by the Reserve Bank of India (RBI) expected in November 2007
  3. New business initiatives—general insurance, private equity
  4. Launch of PSU Bank Benchmark Exchange Traded Scheme (Bank BEES)
  5. Other positive news flows and developments that are expected going forward. 

 

ICICI Bank

Recommendation: Buy

CMP = Rs 1,241

Price target: Rs 1,528

Key points:

  • During Q2FY2008, the core earnings of ICICI bank remained under pressure as retail loans grew at a slower rate and the pressure on spreads continued due to higher deposit costs. However, a large portion of corporate bulk deposits would get repriced in Q1FY2009, which would ease the pressure on spreads going forward.
  • The branch network of the bank increased to 950 branches from 755 in the first six months of FY2008 (post Sangli bank's merger with ICICI bank). The bank also received licences for opening 425 new branches over the next 12 months.
  • The bank reported a 317-basis-point improvement in its current and savings account (CASA) ratio to 25.3% driven by higher current account balances during Q2FY2008. The bank is doing all the right things by building more branches and increasing its CASA base to reduce its reliance on high-cost bulk deposits.
  • The improvement in the cost of funds resulting from the higher CASA ratio is expected only in medium to long term with the increase in branch network. A large portion of high-cost bulk deposits are expected to get repriced in Q1FY2009, which along with the improvement in the CASA ratio should help in improving the spreads going forward. Till then the spreads are likely to remain at current levels.
  • The bank's return on equity (RoE) is likely to remain depressed at 10.5% for FY2008E and FY2009E after the massive capital raising (Rs 20,000 crore raised from primary markets) undertaken by the bank. The low RoE has remained a concern for ICICI Bank, but I expect things to change going forward.
  • With new preference share guidelines in place (more capital raising options available to banks in future resulting in lower equity dilution), a positive outcome on the holding company guidelines from the Reserve Bank of India (that would allow the subsidiaries to take care of their capital needs) and a change in its business model (more branch building expected going forward which should improve its spreads) will help ICICI bank in restoring RoE much faster and then improving the same.
  • I maintain Buy call on this stock with a price target of Rs. 1,528 and time frame of 6-8 months.

Stock Idea - Corporation Bank

Recommendation: Buy

CMP = Rs 471 (as of Monday)

Price target: Rs 542

Result highlights:

  • Corporation Bank's (CORP) Q2FY2008 profit after tax (PAT) grew by 27% year on year (yoy) to Rs 161.3 crore. The growth was primarily driven by a higher non-interest income component. However, the net interest income (NII) growth was better than that of most peers. A surge in the operating expenses due to higher provisioning on account of AS-15 related staff expenses restricted the overall profit growth.
  • CORP's total assets grew by 18% yoy and 5% quarter on quarter (qoq) while the reported NII grew by 17.5% yoy and 7.3% qoq. The NII (adjusted for amortisation) grew by 15.3% yoy and 7% qoq. Its adjusted net interest margin (NIM) showed a sequential improvement unlike many of its peers as it was the only bank that aggressively reduced deposit rates after its dismal NII performance in Q1FY2008 (when NII had seen a growth of 7.8% yoy). 
  • The non-interest income grew by 62% yoy and by 32.3% qoq to Rs 183.2 crore, driven by higher treasury and foreign exchange (forex) incomes. The higher non-interest income growth was the trend for all public sector banks during Q2FY2008.
  • CORP's operating expenses jumped up by 25.3% yoy to Rs 243.2 crore mainly due to a 39.2% jump yoy in the staff expenses brought about by a Rs47-crore AS-15 related expense charged during the quarter. Despite such a sharp jump in the operating expenses, the operating profit growth was robust at 33.4% yoy brought about by a higher non-interest income growth. However, the core operating profit growth was moderate at 8.7% yoy. 
  • The bank's business growth moderated with advances up by 17% yoy from a 25% growth yoy reported during March 2007. The deposit growth also moderated from 28.8% to 20% for the same period. Its total assets grew by 18% yoy compared with a growth of 30% yoy reported in March 2007.
  • The bank's asset quality continues to remain one of the best in the industry with the gross non-performing asset (NPA) down by 21 basis points to 1.9% and the net NPA lower by 11 basis points to 0.35% sequentially. 
  • CORP has been the first bank to cut deposit rates and show some sequential improvement in its NIM in Q2FY2008. The non-interest income growth is expected to be much better in future. It will be driven by higher treasury gains that would help in improving the bank's return on equity (RoE) by 230 basis points to 17.3% in FY2009 from 15% reported in FY2007.
  • The bank's earnings are expected to grow at a compounded annual growth rate (CAGR) of 20.1% between FY2007 and FY2009, which is much better than its past performance. At the current market price of Rs471 the stock is quoting at 8.7x its FY2009E earnings per share (EPS), 4.5x pre-provisioning profit (PPP) and 1.4x FY2009E book value (BV).
  • I maintain Buy recommendation on the stock with a 12-month price target of Rs 542.

Stock Idea - Ipca Laboratories

Recommendation: Buy

CMP = Rs 660 (as of Monday)

Price target: Rs 875

Key points :

  • Domestic formulation business to outpace industry growth: Driven by steady new launches, a strong therapy-focused field force and good brand building abilities, Ipca Laboratories' (Ipca) domestic formulation business has been growing at above industry growth rates. With an enhanced focus towards chronic therapies and aggressive new launches, Ipca's domestic formulation business would continue to grow at 16-18% during FY2007-09.
  • Strong thrust on exports: With steady performance on the domestic front, Ipca is increasingly focusing on its export business, which generates 30% of its total revenues. Driven by aggressive brand promotion in the emerging economies, a revival in the European business and a scale-up in the US business, the formulation exports are projected to grow at a CAGR of 14.5% over FY2007-09.
  • API business to benefit from outsourcing contracts: A leader in several API products, Ipca's API business constitutes 33% of its total revenues. With its low-cost advantage, Ipca is set to capture a substantial chunk of the outsourcing business of global pharmaceutical companies. We believe Ipca's API business will grow at a 13.5% CAGR over FY2007-09, driven by a 9% CAGR in the domestic API business and a 15% CAGR in API exports.
  • Earnings to gallop at a 23% CAGR: We estimate Ipca's earnings to grow at a CAGR of 23% over FY2007-09E on the back of a 20% CAGR in revenues. The revenues will be driven by a 15.3% CAGR in the domestic business and a 24.4% CAGR in exports. We estimate earnings of Rs 59.9 per share in FY2008 and of Rs 73.0 per share in FY2009.
  • Compelling valuations: At the current market price of Rs660, Ipca is trading at attractive valuations of 11.0x FY2008E earnings and 9.0x FY2009E earnings. It has traditionally been getting PE multiple in low teens. But with the enhanced visibility of growth from the US and European markets, the sustained growth in the domestic business and the healthy return ratios, we believe that the stock should command higher valuations.
  • I therefore recommend a Buy on Ipca with a one-year price target of Rs 875.

Stock Idea - Ceat

Recommendation: Buy

CMP = Rs 170 (as of Thursday)

Price target: Rs 216

Result highlights:

  • Ceat's Q2 results were ahead of our expectations on the back of a higher than expected margin. The top line grew by 8.5% led by a volume growth of 7.3% year on year (yoy). Despite a slowdown in the original equipment manufacturer (OEM) sales, which declined by about 30% yoy, the replacement sales and exports did well. 
  • The operating profit margin (OPM) for the quarter grew by 430 basis points to 9.4%, which is the highest in the recent times. Consequently, the operating profit jumped by 102% to Rs 54.6 crore. A lower interest cost and a higher other income led to a whopping 494% growth in the profit to Rs 25.5 crore.
  • Rising rubber and crude prices are a cause for concern. Because of the import threat, the price increase could be minimal, which may lead to some sort of softness in the margins.
  • At the current market price of Rs 170, the stock is trading at 8.3x its FY2008E earnings and at an enterprise value (EV)/earnings before interest, depreciation, tax and amortisation (EBIDTA) of 3.7x.
  • I maintain Buy recommendation on the stock with a price target of Rs 216 with a time frame of 6 months.

Stock Idea - Elder Pharmaceuticals

Recommendation: Buy

CMP = Rs 376 (as of Thursday)

Price target: Rs 508

Result highlights:

  • Elder Pharmaceutical's (Elder) net sales for Q2FY2008 grew by a strong 21.3% to Rs 132.3 crore, thus maintaining the growth momentum seen in the previous quarters. The sales growth was marginally ahead of our estimates of Rs 128 crore and was driven by the continued momentum in the company's star brands and new products and line extensions launched by the company over the past one year. 
  • Elder reported an expansion of 50 basis points in its OPM, which stood at 19.4% during the quarter. The expansion in the OPM was led by a 230-basis-point reduction in the other expenses incurred by the company. The decline in the other expenses was mainly due to the effect of increased productivity of the marketing spend incurred by the company. 
  • Consequently, the company's operating profit rose by 24.5% to Rs 25.6 crore in Q2FY2008.
  • Elder's net profit rose by 21.7% to Rs 17.7 crore in Q2FY2008. The growth in the profit was marginally ahead of our estimate of Rs 15.5 crore and was robust despite an increase of 50.8% in the interest cost and a rise of 53.2% in the depreciation charge during the quarter. The net profit growth was aided by a substantially lower tax provision made during the quarter.
  • Elder is exploring new contract research and manufacturing (CRAMS) opportunities through its 29 alliance partners. Having executed one such project with its Italian partner, Angelini, the company hopes to get 3-4 more such manufacturing contracts from Angelini, which will enable it to scale up its CRAMS business.
  • Elder has recently announced two acquisitions in Europe: a 20% stake in the UK-based Neutra Health PLC and a 51% stake in the Bulgaria-based Biomeda. These two acquisitions will provide Elder an entry into the European markets. Elder plans to complete the Biomeda acquisition by the end of FY2008 and also increase its stake in Neutra Health from 20% currently to 26% by December 2007.
  • At the current market price of Rs 376, the stock is quoting at 9.3x its estimated FY2008 earnings and at 8.3x its estimated FY2009 earnings.
  • I maintain Buy recommendation on the stock with a price target of Rs 508 with time frame of 8-9 months.
 

© blogger templates 3 column | Make Money Online